Celgene 3Q Revenues: $3.0 billion (+28%) 3Q Earnings: $171.4 million (loss of $34.1 million 3Q15) YTD Revenues: $8.2 billion (+23%) YTD Earnings: $1.6 billion (+51%) Comments: REVLIMID sales in the quarter were up 30% to $1.9 billion, driven by new patient market share gains. POMALYST/IMNOVID sales were $341 million, up 33%. OTEZLA sales were $275 million, a 98% increase, driven by market share gains and increased prescriber adoption. ABRAXANE sales were $233 million, up 1%. R&amp...